Recent Research Funding

We receive funding from a variety of sources that recognize the value of our high-impact research.

Rabheh Abdul Aziz, MD, MS

  • Complement C4 in Disease Risk and Pathogenesis of Juvenile Dermatomyositis. Rabheh Abdul Aziz (Co-Investigator). CureJM Foundation. 5/1/2015-4/1/2017.

Stephanie Anzman-Frasca, PhD

  • Understanding the Impact of School-Based Physical Activity Programs. Stephanie Anzman-Frasca (Co-Investigator). NIH. 12/1/2014-11/1/2017.

Robert Baker, MD, PhD

  • A Multicenter, Open Label Study to Evaluate the Safety of Entocort TM EC for the Treatment of Crohn‘s Disease in Pediatric Subjects Aged 5 to 17 Years, Inclusive. Robert Baker (Principal Investigator). AstraZeneca Pharmaceuticals. $38,547. 1/1/2012-2/1/2015.
  • A Multicenter, Open Label Study to Evaluate the Safety of Entocort TM EC for the Maintenance Treatment of Crohn‘s Disease in Pediatric Subjects Aged 5 to 17 Years, Inclusive. Robert Baker (Principal Investigator). AstraZeneca Pharmaceuticals. $16,199. 1/1/2012-2/1/2015.

Susan Baker, MD, PhD

  • Clinical Research Network in Nonalcoholic Steatohepatitis. Susan Baker (Principal Investigator). Swedish Health Services. $29,118. 1/1/2015-6/1/2015.
  • Efficacy, Safety and Tolerability of a Bowel Cleansing Preparation (BLI800) in Pediatric Subjects undergoing Colonoscopy. Susan Baker (Principal Investigator). Braintree Laboratories. $22,786. 7/1/2014-7/1/2015.
  • Predicting Response to Standardized Pediatric Colitis Therapy: The PROTECT Study. Susan Baker (Principal Investigator). Connecticut Children‘s Medical Center. $26,605. 8/1/2012-4/1/2017.
  • Risk Stratification and Identification of Immunogenetic and Microbial Markers of Complicated Disease Course in Pediatric Crohn‘s Disease. Susan Baker (Principal Investigator). Emory University. $39,885. 7/1/2010-6/1/2015.

Matthew Barth, MD

  • Targeting the P13K/Akt Pathway in Therapy Resistant B-cell NHL. Matthew Barth (Principal Investigator). St. Baldricks Foundation. $220,000. 7/1/2013-6/1/2018.

Kathleen Bethin, MD, PhD

  • Efficacy and Safety of Fasteracting Insulin Aspart Compared to NovoRapid Both in Combination with Insulin Degludec in Children and Adolescents with Type 1 Diabetes - Onset Trial Phase 3B. Kathleen Bethin (Principal Investigator). Novo Nordisk. $5,001. 5/1/2016-5/1/2018.
  • A Randomized, Placebo-Controlled, Parallel Group, Multi-Center, Multinational Trial with a 16-Week Double-Blind Period and 36-Week Open-Labeled Period. Kathleen Bethin (Principal Investigator). Novo Nordisk. $12,801. 11/1/2015-11/1/2017.
  • A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of LX4211 in Young Adult Patients with Type 1 Diabetes Mellitus and Elevated Hemoglobin A1C. Kathleen Bethin (Principal Investigator). Lexicon Pharmaceuticals. $192,344. 5/1/2015-4/1/2021.
  • T1D Exchange Clinic Registry Celiac Disease Additional Data Collection. Kathleen Bethin (Principal Investigator). Jaeb Center for Health Research. $9,091. 7/1/2014-10/1/2016.
  • A Randomized, Partial-Blinded, Multi-Center, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Human Plasma-Derived, Alpha-Proteinase Inhibitor, in Children and Adolescents with Recent Onset Type 1 Diabetes Mellitus. Kathleen Bethin (Principal Investigator). Grifols. $9,658. 5/1/2014-10/1/2018.
  • T1D Exchange. Kathleen Bethin (Principal Investigator). Jaeb Center for Health Research. $329,296. 9/1/2010-3/1/2019.
  • T1D Exchange Type 1 Diabetes Network Ancillary Study: Residual C-Peptide in Patients with Type 1 Diabetes. Kathleen Bethin (Principal Investigator). Jaeb Center for Health Research. $8,677. 9/1/2010-3/1/2019.

Gale Burstein, MD, MPH

  • NYSDOH Evaluation of Methods for Improving Screening for Chlamydia among Young Women Seen in Primary Care Settings. Gale Burstein (Co-Investigator). Centers for Disease Control and Prevention. $107,000. 1/1/2015-1/1/2017.

Melinda Cameron, MD

  • Buffalo Regional/WNY Children's Environmental Health Center. Melinda Cameron (Principal Investigator). New York State Department of Health. $45,455. 4/1/2014-3/1/2015.
  • Pre-Doctoral Training in Primary Care. Melinda Cameron (Co-Investigator), Michael Aronica (Co-Investigator), David Holmes (Co-Investigator), Linda Kahn (Co-Investigator), David Milling (Co-Investigator), Andrew Symons (Principal Investigator). Health Resources and Services Admin. $940,252. 9/1/2011-9/1/2016.

Frank Carnevale, MD

  • Study to Compare Adverse Outcomes Before and After Using Bispectral Index Monitor for Procedural Sedation in Children. Frank Carnevale (Co-Principal Investigator). Wildermuth Foundation. $6,152. 1/1/2017-12/1/2017.
  • A Study Examining Visualization of the Larynx in Difficult Intubations Using a Specialized Device Called the “D-Blade”. Frank Carnevale (Co-Principal Investigator), Jeremy Killion (Co-Principal Investigator). Wildermuth Foundation. $4,929. 1/1/2017-12/1/2017.

Praveen Chandrasekharan, MD

  • Neonatal Resuscitation Program – Young Investigator Award: Optimizing Chest Compressions Targeting Gas Exchange and Hemodynamics in a Transitional Cardiac Arrest Model. Praveen Chandrasekharan (Principal Investigator). American Academy of Pediatrics. $15,000. 1/1/2018-12/1/2018.
  • University at Buffalo: Dr. Henry C. and Bertha H. Buswell Fellowship. Praveen Chandrasekharan (Principal Investigator). University at Buffalo. 7/1/2015-6/1/2018.

Leonard Epstein, PhD

  • Enhancing Alternatives to Eating in Infants. Leonard Epstein (Co-Investigator), Kai Ling Kong (Co-Investigator). National Institutes of Health. $2,683,730. 8/1/2016-8/1/2021.
  • Developing the Methodology to Measure Food Reward in Young Infants. Leonard Epstein (Principal Investigator). Innovative Micro-Programs Accelerating Collaboration in Themes (IMPACT). $21,000. 2/1/2016-2/1/2017.
  • Clinical Translational Science Award (CTSA). Leonard Epstein (Co-Investigator), John Canty, Jr. (Co-Principal Investigator), Margarita Dubocovich (Principal Investigator), Peter Elkin (Co-Investigator), Steven Fliesler (Co-Investigator), Alan Hutson (Co-Investigator), Gene Morse (Co-Investigator), Timothy Murphy (Principal Investigator), Sanjay Sethi (Co-Investigator), Laurene Tumiel Berhalter (Co-Investigator). National Institutes of Health. $16,000,000. 1/1/2016-1/1/2020.
  • Delay Discounting as a Target for Self-Regulation in Pre-Diabetes. Leonard Epstein (Co-Principal Investigator), Lucy Mastrandrea (Co-Investigator), Teresa Quattrin (Co-Investigator). National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases. 8/1/2015-7/1/2020.
  • Using Prospection to Improve Obesity Treatment. Leonard Epstein (Principal Investigator), Teresa Quattrin (Co-Investigator). National Institutes of Health/Eunice Kennedy Shriver National Institute of Child Health and Human Development. 1/1/2015-1/1/2019.
  • Habituation to food as a risk factor for pediatric obesity. Leonard Epstein (Principal Investigator). NIH/NIDDK. $2,969,860. 5/1/2012-4/1/2017.
  • The influence of pricing and nutrient profiling on food purchases. Leonard Epstein (Principal Investigator). NIH/NCI. $1,721,603. 4/1/2012-3/1/2015.

Richard Erbe, MD, FACMG

  • A Multicenter, Randomized, Placebo-Controlled Study of SBC-102 in Patients with Lysosomnal Acid Lipase Deficiency. Richard Erbe (Principal Investigator). INC Research. $46,575. 4/1/2013-4/1/2015.

Howard Faden, MD

  • Research on C. difficile. Howard Faden (Principal Investigator). Wildermuth Foundation. $20,000. 1/1/2016-12/1/2016.

Danielle Goetz, MD

  • A Phase 3, Open-Label Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age. Danielle Goetz (Principal Investigator). Vertex Pharmaceuticals. $7,751. 2/1/2015-2/1/2017.
  • Use of Lung Clearance Index to Measure Change in Airways Obstruction in Inpatients with Cystic Fibrosis. Danielle Goetz (Principal Investigator). Women and Children's Hospital of Buffalo. 7/1/2014-7/1/2015.
  • The EPIC Observational Longitudinal Assessment of Risk Factors For and Impact of Pseudomonas aeruginosa Acquisition and Early Anti-Pseudomonal Therapy in Children with Cystic Fibrosis. Danielle Goetz (Principal Investigator). Cystic Fibrosis Foundation Therapeutics. $29,045. 3/1/2014-3/1/2019.
  • Quality Improvement Project on Depression Screening. Danielle Goetz (Co-Investigator). Cystic Fibrosis Foundation. $10,500. 1/1/2014-1/1/2017.

Oscar Gómez, MD, PhD

  • Studies on Emergent Diarrheagenic E. coli Pathogens. Oscar Gómez (Principal Investigator). National Institutes of Health/National Institute of Allergy and Infectious Disease. $269,000. 1/1/2012-1/1/2017.

Michelle Hartley-McAndrew, MD

  • Conversations in the Disciplines. Michelle Hartley-McAndrew (Co-Principal Investigator). SUNY University Faculty Senate. $4,309. 6/1/2017-3/1/2018.

Mark Hicar, MD, PhD

  • Antibody and B-Cell Characterization During Acute Kawasaki Disease. Mark Hicar (Principal Investigator). Wildermuth Research Foundation. $25,000. 5/1/2016-4/1/2017.
  • The Role of Non-Broadly Neutralizing Antibodies Targeting gp41 Structural Epitopes in Long-Term Nonprogression of HIV Infection. Mark Hicar (Principal Investigator). National Institute of Allergy and Infectious Diseases. $1,900,000. 2/1/2016-1/1/2021.
  • A His-Tag Binding Membrane System for Generating Neutralizing GP41 MPER Antibodies. Mark Hicar (Co-Investigator), Jonathan Lovell (Principal Investigator). National Institutes of Health. $250,000. 1/1/2016-12/1/2017.

Lucy Holmes, MD, MPH

  • Individual Development Awards Program. Lucy Holmes (Principal Investigator). United University Professions. $1,000. 1/1/2017-12/1/2017.

Shilpa Jain, MD, MPH

  • My Life, Our Future: A Hemophilia Genotyping Initiative Date and Sample Research Repository. Shilpa Jain (Principal Investigator). American Thrombosis and Hemostasis Network. $3,501. 4/1/2016-12/1/2017.

James Jarvis, MD

  • Genetics and Epigenetics in JIA CD4 T Cells. James Jarvis (Principal Investigator). American College of Rheumatology Research and Education Foundation. $400,000. 7/1/2017-6/1/2019.
  • Developing Biomarkers for Juvenile Arthritis from Plasma Exosomes. James Jarvis (Principal Investigator). Wildermuth Foundation. $25,000. 6/1/2017-5/1/2018.
  • Interplay Between Genetics and Epigenetics in Polyarticular JIA. James Jarvis (Principal Investigator). Arthritis Foundation. $730,998. 1/1/2017-12/1/2018.
  • Plasma Exosomes in Juvenile Dermatomyositis. James Jarvis (Principal Investigator). Cure JM Foundation. $25,000. 7/1/2016-5/1/2018.

Kara Kelly, MD

  • Columbia University Minority/Underserved NCI Community Oncology Research Program. Kara Kelly (Principal Investigator). National Cancer Institute. $3,250,000. 8/1/2014-7/1/2019.
  • Integrative Therapies Program for Children with Cancer. Kara Kelly (Principal Investigator). Tamarind Foundation. 11/1/1998-10/1/2017.

Jeremy Killion, MD

  • A Study Examining Visualization of the Larynx in Difficult Intubations Using a Specialized Device Called the “D-Blade”. Jeremy Killion (Co-Principal Investigator), Frank Carnevale (Co-Principal Investigator). Wildermuth Foundation. $4,929. 1/1/2017-12/1/2017.

Kai Ling Kong, PhD

  • Enhancing Alternatives to Eating in Infants. Kai Ling Kong (Co-Investigator), Leonard Epstein (Co-Investigator). National Institutes of Health. $2,683,730. 8/1/2016-8/1/2021.
  • Developing the Methodology to Measure Food Reward in Young Infants (3-6 months old). Kai Ling Kong (Principal Investigator). University at Buffalo IMPACT. $21,000. 2/1/2016-2/1/2017.
  • Methodology to Measure Infant Food Reinforcement. Kai Ling Kong (Principal Investigator). Research Institute on Addictions. $24,491. 11/1/2015-10/1/2016.
  • CTSA Pilot: Pilot Study on Pediatric Obesity Prevention by Maternal Smoking Cessation in Pregnancy and Lactation. Kai Ling Kong (Co-Investigator), Xiaozhong Wen (Principal Investigator). National Institutes of Health. $75,000. 11/1/2015-3/1/2017.

Dennis Kuo, MD, MHS

  • Building Health Through Care Coordination for Children with Medical Complexity. Dennis Kuo (Principal Investigator). Lucille Packard Foundation for Children‘s Health. $68,903. 5/1/2017-4/1/2018.

Corinne Leach, MD, PhD

  • Hypothermia in the Late Preterm Infant. Corinne Leach (Principal Investigator). Eunice Kennedy Shriver National Institute of Child Health and Human Development. $1,200,000. 1/1/2015-1/1/2017.

Heather Lehman, MD, FAAAI

  • Defining and Treating a New Pediatric Asthma Endotype: Depression-Related Asthma Mediated by the Cholinergic Pathway. Heather Lehman (Principal Investigator). University at Buffalo. $47,000. 7/1/2016-6/1/2017.
  • Treating Caregiver Depression to Improve Childhood Asthma: Impact and Mediators. Heather Lehman (Co-Investigator), Bruce Miller (Principal Investigator), Beatrice Wood (Principal Investigator). NIH/NHLBI. $3,987,363. 8/1/2015-7/1/2020.

Lucy Mastrandrea, MD, PhD

  • A Phase 3, Double-Blind, Placebo-Controlled, Randomized, Multi-Center Study to Assess the Safety and Efficacy of Exenatide Once Weekly in Adolescents with Type 2 Diabetes and Clinical Study NO D55. Lucy Mastrandrea (Principal Investigator). AstraZeneca. 1/1/2017-1/1/2020.
  • A 6-Month, Multi-Center, Randomized, Open-Label, 2-Arm, Parallel Group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus Injected Once Daily in Children and Adolescents with Type 1 Diabetes. Lucy Mastrandrea (Principal Investigator). Sanofi. 12/1/2016-12/1/2018.
  • Effect pf Liraglutide for Weight Management in Pubertal Adolescent Subjects with Obesity. A 56-Week, Double-Blind, Randomized, Parallel Group, Placebo-Controlled, Multi-National Trial. Lucy Mastrandrea (Principal Investigator). NovoNordisk. 11/1/2016-11/1/2018.
  • A 24-Week, Multicenter, Randomized, Double-Blind, Parallel Group, Phase 3 Trial with a 28-Week Long-Term Safety Extension Phase Evaluating the Safety and Efficacy of Dapagliflozin 10 mg in T2DM Subjects Age 10-24 Years. Lucy Mastrandrea (Principal Investigator). AstraZeneca. 9/1/2016-9/1/2018.
  • A Randomized, Double-Blind, Placebo-Controlled Trial to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 Years. Lucy Mastrandrea (Principal Investigator). Novo Nordisk. 5/1/2016-5/1/2018.
  • Accu-Chek Connect at School (CATS) Pediatric Study. Lucy Mastrandrea (Principal Investigator). Roche. $5,001. 2/1/2016-12/1/2017.
  • Delay Discounting as a Target for Self-Regulation in Pre-Diabetes. Lucy Mastrandrea (Co-Investigator), Leonard Epstein (Co-Principal Investigator), Teresa Quattrin (Co-Investigator). National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases. 8/1/2015-7/1/2020.
  • Targeting Polyamines Using DFMO in Persons with T1D. Lucy Mastrandrea (Principal Investigator). Indiana University Board of Trustees. $93,769. 3/1/2015-2/1/2018.
  • Efficacy and Safety of Liraglutide in Combination with Metformin vs. Metformin on Glycaemic Control in Children and Adolescents with Type 2 Diabetes - A 26-Week Double-Blind, Randomized, Parallel Group, Placebo-Controlled Multi-Center Trial. Lucy Mastrandrea (Principal Investigator). Novo Nordisk. $9,601. 2/1/2015-1/1/2018.
  • A 26-Week Open-Label, Randomized, 2-Armed, Parallel Group, Multi-Centre Trial Investigating Efficacy and Safety of Insulin Determir vs. Insulin Neutral Protamine Hagedorn in Combination with Metformin and Diet/Exercise. Lucy Mastrandrea (Principal Investigator). Novo Nordisk. $18,395. 9/1/2014-8/1/2017.

Jayasree Nair, MD

  • Neonatal Resuscitation Program - Research Grant Award: Delayed Cord Clamping in Term Lambs with Asystolic Cardiac Arrest. Jayasree Nair (Principal Investigator). American Academy of Pediatrics. $50,000. 1/1/2018-12/1/2018.
  • Role of Sustained Inflation and Delayed Cord Clamping in Resuscitation After Asphyxia. Jayasree Nair (Principal Investigator). Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD). $79,750. 7/1/2016-6/1/2018.
  • Air Pollution Exposure During Pregnancy: Birth Outcomes and Infant Development, A Cohort Study. Jayasree Nair (Co-Investigator). University at Buffalo Community for Global Health Equity. $35,000. 5/1/2016-5/1/2018.

Teresa Quattrin, MD

  • Delay Discounting as a Target for Self-Regulation in Pre-Diabetes. Teresa Quattrin (Co-Investigator), Leonard Epstein (Co-Principal Investigator), Lucy Mastrandrea (Co-Investigator). National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases. 8/1/2015-7/1/2020.
  • Using Prospection to Improve Obesity Treatment. Teresa Quattrin (Co-Investigator), Leonard Epstein (Principal Investigator). National Institutes of Health/Eunice Kennedy Shriver National Institute of Child Health and Human Development. 1/1/2015-1/1/2019.
  • The Western New York Project for Pediatric Obesity Prevention (WNYOPP). Teresa Quattrin (Principal Investigator). New York State Department of Health. $675,000. 1/1/2011-1/1/2016.

Munmun Rawat, MD

  • Vasopressin and Epinephrine in Neonatal Resuscitation. Munmun Rawat (Principal Investigator). University at Buffalo: Dr. Henry C. and Bertha H. Buswell Fellowship. 3/1/2017-3/1/2020.
  • Use of Vasopressin in Neonatal Resuscitation. Munmun Rawat (Principal Investigator). Canadian Paediatric Society: Neonatal Resuscitation Program. $12,500. 1/1/2017-1/1/2018.

Anne Marie Reynolds, MD, MPH

  • Data Coordinating Center for the Prematurity and Respiratory Outcomes Program. Anne Marie Reynolds (Principal Investigator). University of Rochester. $69,180. 5/1/2011-4/1/2015.
  • Prematurity and Respiratory Outcomes Capitation Agreement. Anne Marie Reynolds (Principal Investigator). University of Rochester. $111,400. 5/1/2011-4/1/2015.
  • Neonatal Research Network. Anne Marie Reynolds (Co-Investigator), Osman Farooq (Co-Investigator). NICHD. 4/1/2011-4/1/2021.
  • Functional and Lymphocytic Markers of Respiratory Morbidity in Hyperoxic Preemies. Anne Marie Reynolds (Principal Investigator). University of Rochester. $379,288. 5/1/2010-4/1/2015.
  • Prematurity and Respiratory Outcomes Program (PROP) - Functional and Lymphocytic Markers of Respiratory Morbidity in Hyperoxic Preemies Studying the Effect of Oxygenation on Lymphocyte Phenotype. Anne Marie Reynolds (Principal Investigator). NHLBI. $1,797,345. 1/1/2010-1/1/2015.

Denise Rokitka, MD, MPH

  • Feasibility of an Exercise Intervention to Enhance Fitness and QOL Among Adult Survivors of Childhood Cancer. Denise Rokitka (Principal Investigator). Roswell Alliance Foundation. $30,000. 1/1/2014-1/1/2015.
  • Cognitive Functioning and Depression Among Young Adult Survivors of Childhood and Adolescent Cancer. Denise Rokitka (Principal Investigator). Hyundai Hope on Wheels. $250,000. 1/1/2014-1/1/2016.

Shipra Singh, MD, MPH

  • Success with Therapies Research Consortium. Shipra Singh (Principal Investigator). Cystic Fibrosis Foundation. $25,000. 8/1/2014-7/1/2017.

Xiaozhong Wen, PhD

  • CTSA Pilot: Pilot Study on Pediatric Obesity Prevention by Maternal Smoking Cessation in Pregnancy and Lactation. Xiaozhong Wen (Principal Investigator), Kai Ling Kong (Co-Investigator). National Institutes of Health. $75,000. 11/1/2015-3/1/2017.
  • Maternal Low-Fat Vegetarian Diet to Prevent Gestational-Diabetes-Related Childhood Obesity: A Pilot Randomized Controlled Trial. Xiaozhong Wen (Principal Investigator). SUNY REACH (Research Excellence in Academic Health). $25,000. 9/1/2013-8/1/2015.